VELCADE (BORTEZOMIB)
VELCADE (BORTEZOMIB) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: VELCADE; Generic name: BORTEZOMIB; Drug class: Proteasome Inhibitor [EPC].
| Brand name | VELCADE |
|---|---|
| Generic name | BORTEZOMIB |
| Drug class | Proteasome Inhibitor [EPC] |
| Manufacturer | Takeda Pharmaceuticals America, Inc. |
| Used for | 1 INDICATIONS AND USAGE VELCADE is a proteasome inhibitor indicated for: treatment of adult patients with multiple myeloma ( 1.1 ) treatment of adult patients with mantle cell lymphoma ( 1.2 ) 1.1 Multiple Myeloma VELCADE is indicated for the treatment of adult patients with multiple myeloma. 1.2 Mantle Cell Lymphoma VELCADE is indicated for the treatment of adult patients with mantle cell lymphoma. |
| Dosage | 2 DOSAGE AND ADMINISTRATION For subcutaneous or intravenous use only. Each route of administration has a different reconstituted concentration. Exercise caution when calculating the volume to be administered. ( 2.1 , 2.10 ) The recommended starting dose of VELCADE is 1.3 mg/m 2 administered either as a 3 to 5 second bolus intravenous injection or subcutaneous injection. ( 2.2 , 2.4 , 2.6 ) Retreatment for Multiple Myeloma: May retreat starting at the last tolerated dose. ( 2.6 ) Hepatic Impairme |
| Active ingredient(s) | BORTEZOMIB |
| Route | INTRAVENOUS |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1521d321-e724-4ffc-adad-34bf4f44fac7 |